San Diego, California, April 24, 2019 – Forge Therapeutics, Inc. (Forge) and Basilea Pharmaceutica International Ltd. (Basilea), a wholly-owned subsidiary of Basilea [...]
-Presentation will focus on Forge’s novel chemistry platform, BLACKSMITH, and its therapeutic applications- San Diego, California, March 12, 2019 – Forge Therapeutics, Inc. [...]
San Diego, California, January 3, 2019 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, announced today that [...]
-Technical milestone achievement and program advancement from initial round of ‘Powered by CARB-X’ products- San Diego, California, August 1, 2018 – Forge Therapeutics, [...]
2018 BIO International, ASM Microbe, and GRC Metals in Medicine San Diego, California, May 21, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology [...]
San Diego, California, April 9, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that David [...]
-Presentation will focus on Forge’s portfolio of four novel classes of antibiotics to treat deadly ‘superbug’ infections from Gram-negative bacteria- San Diego, California, [...]
San Diego, California, March 19, 2018 – Forge Therapeutics, Inc. (Forge), a biotechnology company developing novel medicines targeting metalloenzymes, today announced that Professor [...]
-"What it Means to be Handcrafted in San Diego" Open House Event to Commemorate New Space- San Diego, California, March 12, 2018 – Forge [...]
-Data demonstrates broad applicability for LpxC inhibitor in Acinetobacter baumannii, a life-threatening respiratory bacteria- LpxC antibiotic is Forge’s flagship program stemming from BLACKSMITH [...]
